Medication related jaw osteonecrosis (MRONJ) late onset 3 years after
IPILIMUMAB endovenous administration: a possible role of target therapy
Ipilimumab has been associated to medication related jaw osteonecrosis
(MRONJ) only two times in literature. A woman underwent therapy with
ipilimumab for Metastatic Melanoma in 2015 and she developed MRONJ in
2018. She was successfully treated with medical therapy alone. Vigilance
in dental management of these patients is needed.